ClinicalTrials.gg
CompletedNCT00154388Updated Nov 18, 2016

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

A Phase 2 interventional study of Imatinib mesylate in Life Threatening Diseases, sponsored by Novartis Pharmaceuticals. Completed. Open to participants aged 15 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-11-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
185
Allocation
Non-randomized
Ages
15 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Adenocarcinoma by Novartis — 2 open to participants now, 2 under way, none of them phase 3. Adenocarcinoma · Novartis.

Enrollment
6th of 14
185 · median 79
Started
2001
the only one that year
Phase 2
8 of 14
none open now
Registered
1st of 14
by date

Among the 14 studies in Adenocarcinoma by Novartis, this one is the 6th largest by enrollment, is the only one that started in 2001, is one of 8 in phase 2, and was the 1st registered.

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

2 of the 14 studies in Adenocarcinoma by Novartis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 15 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Adenocarcinoma by Novartis, or all of them as a file.
02

Study summary

Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease.

03

Conditions studied

  • Life Threatening Diseases

Keywords

  • adenocarcinoma
  • leiomyosarcoma
  • angiosarcoma
  • synovial sarcoma
  • myelodysplastic syndrome/HES
  • CMML
  • multiple myeloma
  • embryonal rhabdomyosarcoma
  • endometrial sarcoma
  • adenoid cystic carcinoma
  • fibromatosis
  • ductal invasive breast carcinoma
  • chondrosarcoma
  • pleural tumor
  • brenner tumor
  • ewing sarcoma
  • round cell tumor
  • seminoma
  • thymic carcinoma
  • malignant melanoma
  • fibrosarcoma breast
  • dermatofibrosarcoma protuberans
  • DFSP
  • ovarian stromal tumor
  • osteosarcoma
  • chorioideal melanoma
  • hemangiopericytoma
  • myelofibrosis
  • liposarcoma
  • SCLC
  • small cell lung carcinoma
  • hypereosinophilic syndrome
  • chronic myelo-monocytic leukemia
  • neurofibrosarcoma
  • mesothelioma
  • malignant mesenchymoma
  • malignant schwannoma
  • mast cell leukemia / mastocytosis
  • renal cell carcinoma
  • malignant histocytoma
  • chordoma
04

Who can participate

Ages eligible
15 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 15 years of age
  • Life threatening disease documented by conventional criteria to be resistant to standard, approved therapy.
  • Experimental documentation of functional significance of either Abl, Kit (CD117), or PDGF-R in the relevant target tissue (preferably on a sample taken within 6 weeks of study entry).
  • Performance status of 0, 1, or 2.
  • Adequate end organ function defined as: total \< 1.5 x , and SGPT \< 2.5 x UNL (or \< 5 x ULN for patients with hepatic disease), creatinine \< 1.5 x ULN, > 1.5 x 109/L, > 100 x 109/L.
  • Negative serum or urine pregnancy test for women of child bearing potential () within 7 days of study initiation. Post menopausal women must have experienced amenorrhea for at least 12 months. Male and female patients must use effective methods throughout the study and for up to 3 months after study discontinuation.
  • of more than 3 months.
  • Written, voluntary, for retrieval, evaluation and use of tissue samples.

Exclusion criteria

Exclusion Criteria:

  • Patients who have received any other agent within 28 days of study initiation.
  • Patients with another primary except if other primary malignancy is neither currently nor requiring active intervention.
  • Patients with Grade III/IV cardiac problems defined by the Criteria (e.g. congestive heart failure, myocardial infarction within 6 months of study).
  • Female patients who are pregnant or breast-feeding.
  • Patients who have another severe and/or life threatening medical disease.
  • Patients with acute or known chronic liver disease (e.g. chronic active hepatitis, cirrhosis).
  • Patients with a known diagnosis of the ((HIV) infection.
  • Patients who have received chemotherapy within 4 weeks (6 weeks allowed for nitrosourea, mitomycin-C or any antibody therapy) prior to study entry.
  • Patients who have had major surgery within 2 weeks prior to study entry.
  • Patients with any significant history of non-compliance to medical regimens or with inability to grant reliable .

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
185 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. To examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate-sensitive tyrosine kinases

  2. To identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease

Secondary outcomes

  1. To assess the safety and tolerability of Imatinib mesylate

  2. To evaluate the pharmacokinetic profile of Imatinib mesylate

  3. To assess, where feasible, the functional significance of relevant signal-transduction components in target tissues

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, Samuels BL, Baker LH. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009 Jul 1;27(19):3148-53. doi: 10.1200/JCO.2008.20.5054. Epub 2009 May 18. Erratum In: J Clin Oncol. 2009 Sep 20;27(27):4630. Myers, Paul A [corrected to Meyers, Paul A]. PubMed 19451433 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2001, a primary completion of Jan 2007 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 12, 2005
Start
Feb 2001
Primary completionActual
Jan 2007
CompletionActual
Jan 2007
Last update
Nov 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00154388
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Feb 2001
Primary completion
Jan 2007
Completion
Jan 2007
Last update
Nov 18, 2016

Study contacts

Michael Heinrich, MD
principal investigator · Oregon Health and Science University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion